Benutzer:Benff/Unterseite EU-MA
aus Wikipedia, der freien Enzyklopädie
EU-Arzneimittelzulassungen (human) • EU-Arzneimittelzulassungen (veterinär)
EU-Register-Nr.[3] | Arzneimittel-Name | MA-Inhaber | MA-Datum | Wirkstoff(e) | ATC-Code | Anm.[4] |
---|---|---|---|---|---|---|
pending | Beyfortus neu | AstraZeneca AB | Nirsevimab | |||
pending | Enjaymo neu | Genzyme Europe BV | Sutimlimab | L04AA55 | O | |
pending | Livtencity neu | Takeda Pharmaceuticals International AG Ireland Branch | Maribavir | J05AX10 | O | |
pending | Melatonin Neurim neu | RAD Neurim Pharmaceuticals EEC SARL | Melatonin | N05CH01 | ||
pending | Mycapssa neu | Amryt Pharmaceuticals DAC | Octreotid | H01CB02 | O | |
pending | Pyrukynd neu | Agios Netherlands B.V. | Mitapivat | B06AX04 | O, C | |
pending | Zynlonta neu | ADC Therapeutics (NL) B.V. | Loncastuximab-Tesirin | L01FX22 | O | |
pending | Ximluci neu | STADA Arzneimittel AG | Ranibizumab | S01LA04 | B | |
pending | Teriparatide SUN neu | Sun Pharmaceutical Industries Europe B.V. | Teriparatid | H05AA02 | ||
pending | Sorafenib Accord neu | Accord Healthcare S.L.U. | Sorafenib | L01EX02 | G | |
pending | Teriflunomide Accord neu | Accord Healthcare S.L.U. | Teriflunomid | L04AA31 | G | |
pending | Teriflunomide Mylan neu | Mylan Pharmaceuticals Limited | Teriflunomid | L04AA31 | G | |
pending | Amvuttra | Alnylam Netherlands B.V. | Vutrisiran | O | ||
pending | Celdoxome pegylated liposomal | YES Pharmaceutical Development Services GmbH | Doxorubicin | L01DB01 | ||
pending | Illuzyce | Billev Pharma Aps | Lutetium(177Lu)chlorid | V10X | ||
pending | Lupkynis | Otsuka Pharmaceutical Netherlands B.V. | Voclosporin | L04AD03 | ||
pending | Mounjaro | Eli Lilly Nederland B.V. | Tirzepatid | A10B | ||
pending | Nulibry | Comharsa Life Sciences Ltd | Fosdenopterin | A16AX19 | O, E | |
pending | Tezspire | AstraZeneca AB | Tezepelumab | R03DX11 | ||
pending | Thalidomide Lipomed | Lipomed GmbH | Thalidomid | L04AX02 | ||
pending | Vabysmo | Roche Registration GmbH | Faricimab | |||
pending | Rayvow | Eli Lilly Nederland B.V. | Lasmiditan | N02CC08 | ||
EU/1/22/1679 neu | Opdualag | Bristol-Myers Squibb Pharma EEIG | 15.09.2022 | Relatlimab / Nivolumab | L01XY03 | |
EU/1/22/1673 | Ranivisio | Midas Pharma GmbH | 25.08.2022 | Ranibizumab | S01LA04 | B |
EU/1/22/1670 | Scemblix | Novartis Ireland Limited | 25.08.2022 | Asciminib | L01EA06 | O |
EU/1/22/1668 | Roctavian | BioMarin International Limited | 24.08.2022 | Valoctocogen roxaparvovec | B02B02 | O, C |
EU/1/22/1675 | Tecvayli | Janssen-Cilag International N.V. | 23.08.2022 | Teclistamab | O, A, C | |
EU/1/22/1671 | Sunlenca | Gilead Sciences Ireland Unlimited Company | 17.08.2022 | Lenacapavir | J05AX31 | |
EU/1/22/1669 | Pepaxti | Oncopeptides AB | 17.08.2022 | Melphalanflufenamid | L01AA10 | |
EU/1/22/1667 | Vegzelma | Celltrion Healthcare Hungary Kft. | 17.08.2022 | Bevacizumab | L01XC07 | B |
EU/1/22/1674 | Vyvgart | Argenx | 10.08.2022 | Efgartigimod alfa | L04AA58 | O |
EU/1/22/1661 | Sitagliptin / Metformin hydrochloride Accord | Accord Healthcare S.L.U. | 22.07.2022 | Sitagliptin / Metforminhydrochlorid | A10BD07 | G |
EU/1/22/1660 | Zokinvy | EigerBio Europe Limited | 18.07.2022 | Lonafarnib | O, E | |
EU/1/22/1653 | Upstaza | PTC Therapeutics International Limited | 18.07.2022 | Eladocagen exuparvovec | O, E | |
EU/1/22/1664 | Cevenfacta | Laboratoire français du Fractionnement et des Biotechnologies | 15.07.2022 | Eptacog beta (aktiviert) | B02BD08 | |
EU/1/22/1663 | Sugammadex Fresenius Kabi | Fresenius Kabi Deutschland GmbH | 15.07.2022 | Sugammadex | V03AB35 | G |
EU/1/22/1658 | Ganirelix Gedeon Richter | Gedeon Richter Plc. | 15.07.2022 | Ganirelix | H01CC01 | G |
EU/1/22/1657 | Kinpeygo | Calliditas Therapeutics AB | 15.07.2022 | Budesonid | O, C | |
EU/1/22/1656 | Ertapenem SUN | Sun Pharmaceutical Industries Europe B.V. | 15.07.2022 | Ertapenem | J01DH03 | |
EU/1/22/1659 | Xenpozyme | Genzyme Europe B.V. | 24.06.2022 | Olipudase alfa | O | |
EU/1/21/1579 | Nexviadyme | Genzyme Europe B.V. | 24.06.2022 | Avalglucosidase alfa | ||
EU/1/21/1624 | COVID-19 Vaccine Valneva (inactiviert, adjuvantiert) | Valneva Austria GmbH | 24.06.2022 | COVID-19-Impfstoff (inaktiviert, adjuvantiert, adsorbiert) | J07BX03 | |
EU/1/22/1652 | Filsuvez | Amryt Pharmaceuticals DAC | 21.06.2022 | Birkenrindenextrakt | D03AX13 | O |
EU/1/22/1650 | Tabrecta | Novartis Ireland Limited | 20.06.2022 | Capmatinib | ||
EU/1/22/1655 | Pirfenidone AET | Alfred E. Tiefenbacher (GmbH & Co. KG) | 20.06.2022 | Pirfenidon | G | |
EU/1/21/1606 | Yselty | ObsEva Ireland Ltd. | 14.06.2022 | Linzagolix-Cholin | ||
EU/1/22/1649 | Lunsumio | Roche Registration GmbH | 03.06.2022 | Mosunetuzumab | L01XC | O, C |
EU/1/22/1629 | Zolsketil pegylated liposomal | Accord Healthcare S.L.U. | 31.05.2022 | Doxorubicin | L01DB01 | |
EU/1/22/1648 | Carvykti | Janssen-Cilag International N.V. | 25.05.2022 | Ciltacabtagen autoleucel | O, C | |
EU/1/22/1647 | Camcevi | Accord Healthcare S.L.U. | 24.05.2022 | Leuprorelin | L02AE02 | |
EU/1/22/1646 | Amifampridine SERB | SERB S.A. | 19.05.2022 | Amifampridin | N07XX05 | G |
EU/1/22/1637 | Dimethyl fumarate Neuraxpharm | Laboratorios Lesvi, S.L. | 13.05.2022 | Dimethylfumarat | L04AX07 | G |
EU/1/22/1634 | Dimethyl fumarate Mylan | Mylan IRE Healthcare Limited | 13.05.2022 | Dimethylfumarat | L04AX07 | G |
EU/1/22/1635 | Dimethyl fumarate Polpharma | Zakłady Farmaceutyczne POLPHARMA S.A. | 13.05.2022 | Dimethylfumarat | L04AX07 | G |
EU/1/22/1640 | Amversio | SERB S.A. | 05.05.2022 | Betain, wasserfrei | A16AA06 | G |
EU/1/22/1642 | Orgovyx | Accord Healthcare S.L.U. | 29.04.2022 | Relugolix | L02BX04 | |
EU/1/22/1638 | Quviviq | Idorsia Pharmaceuticals Deutschland GmbH | 29.04.2022 | Daridorexant | ||
EU/1/21/1602 | Uplizna | Horizon Therapeutics Ireland DAC | 25.04.2022 | Inebilizumab | L04AA47 | |
EU/1/22/1644 | Inpremzia | Baxter Holding B.V. | 25.04.2022 | Insulin human (rDNA) | A10AB01 | B |
EU/1/22/1643 | Kapruvia | Vifor Fresenius Medical Care Renal Pharma France | 25.04.2022 | Difelikefalin | V03AX04 | |
EU/1/22/1641 | PreHevbri | VBI Vaccines B.V. | 25.04.2022 | Hepatitis-B-Oberflächenantigen (Hepatitis-B-Impfstoff, rekombinant, adsorbiert) | J07BC01 | |
EU/1/22/1645 | Vydura | Biohaven Pharmaceutical Ireland DAC | 25.04.2022 | Rimegepant | N02CD | |
EU/1/22/1639 | Truvelog Mix 30 | Sanofi-Aventis groupe | 25.04.2022 | Insulin aspart | A10AD05 | B |
EU/1/22/1633 | Sitagliptin Accord | Accord Healthcare S.L.U. | 25.04.2022 | Sitagliptin | A10BH01 | G |
EU/1/21/1615 | Padcev | Astellas Pharma Europe B.V. | 13.04.2022 | Enfortumab vedotin | L01FX13 | |
EU/1/22/1631 | Breyanzi | Bristol Myers Squibb Pharma EEIG | 04.04.2022 | Lisocabtagen maraleucel | L01 | |
EU/1/22/1630 | Kimmtrak | Immunocore Ireland Limited | 01.04.2022 | Tebentafusp | O | |
EU/1/22/1632 | Stimufend | Fresenius Kabi Deutschland GmbH | 28.03.2022 | Pegfilgrastim | L03AA13 | B |
EU/1/22/1651 | Evusheld | AstraZeneca AB | 25.03.2022 | Tixagevimab / Cilgavimab | ||
EU/1/22/1628 | Sondelbay | Accord Healthcare S.L.U. | 24.03.2022 | Teriparatid | H05AA02 | B |
EU/1/21/1611 | Vildagliptin/Metformin hydrochloride Accord | Accord Healthcare S.L.U. | 24.03.2022 | Vildagliptin / Metforminhydrochlorid | A10BD08 | G |
EU/1/21/1578 | Ontilyv | Bial Portela & Companhia S.A. | 21.02.2022 | Opicapon | N04BX04 | |
EU/1/21/1619 | Metformin hydrochloride Mylan | Mylan IRE Healthcare Limited | 16.02.2022 | Sitagliptin / Metforminhydrochlorid | A10BD07 | G |
EU/1/21/1620 | Sapropterin Dipharma | Dipharma B.V. | 16.02.2022 | Sapropterin | A16AX07 | |
EU/1/21/1616 | Kerendia | Bayer AG | 16.02.2022 | Finerenon | C03DA05 | |
EU/1/21/1596 | Tepmetko | Merck Europe B.V. | 16.02.2022 | Tepotinib | L01EX21 | |
EU/1/21/1623 | Saphnelo | AstraZeneca AB | 14.02.2022 | Anifrolumab | L04AA | |
EU/1/21/1622 | Oxbryta | Global Blood Therapeutics Netherlands B.V. | 14.02.2022 | Voxelotor | B06AX03 | O |
EU/1/21/1621 | Okedi | Laboratorios Farmacéuticos Rovi, S.A. | 14.02.2022 | Risperidon | N05AX08 | |
EU/1/21/1617 | Ngenla | Pfizer Europe MA EEIG | 14.02.2022 | Somatrogon | H01AC08 | O |
EU/1/21/1612 | Apexxnar | Pfizer Europe MA EEIG | 14.02.2022 | Pneumokokken-Konjugatimpfstoff (20-valent, adsorbiert) | J07AL02 | |
EU/1/22/1625 | Paxlovid | Pfizer Europe MA EEIG | 28.01.2022 | Nirmatrelvir / Ritonavir | C | |
EU/1/21/1599 | Vyepti | H. Lundbeck A/S | 24.01.2022 | Eptinezumab | N02CD05 | |
EU/1/21/1605 | Tavneos | Vifor Fresenius Medical Care Renal Pharma France | 11.01.2022 | Avacopan | O, O | |
EU/1/21/1607 | Lonapegsomatropin Ascendis Pharma | Ascendis Pharma Endocrinology Division A/S | 11.01.2022 | Lonapegsomatropin | O | |
EU/1/21/1586 | Voraxaze | SERB SAS | 11.01.2022 | Glucarpidase | V03AF09 | O, E |
EU/1/21/1604 | Riltrava Aerosphere | AstraZeneca AB | 06.01.2022 | Formoterol / Glycopyrroniumbromid / Budesonid | R03AL11 | |
EU/1/21/1608 | Wegovy | Novo Nordisk A/S | 06.01.2022 | Semaglutid | A10BJ06 | |
EU/1/21/1603 | Lumykras | Amgen Europe B.V. | 06.01.2022 | Sotorasib | L01XX73 | |
EU/1/21/1600 | Tecovirimat SIGA | SIGA Technologies Netherlands B.V. | 06.01.2022 | Tecovirimat | J05AX24 | |
EU/1/21/1618 | Nuvaxovid | Novavax CZ, a.s. | 20.12.2021 | COVID-19-Impfstoff (rekombinant, adjuvantiert) | J07BX03 | C |
EU/1/21/1562 | Xevudy | GlaxoSmithKline Trading Services Limited | 17.12.2021 | Sotrovimab | J06BD05 | |
EU/1/21/1595 | Aspaveli | Swedish Orphan Biovitrum AB (publ) | 13.12.2021 | Pegcetacoplan | L04AA54 | O |
EU/1/21/1591 | Vaxneuvance | Merck, Sharp & Dohme B.V. | 13.12.2021 | Pneumokokken-Konjugatimpfstoff (15‑valent, adsorbiert) | J07AL02 | |
EU/1/21/1598 | Sitagliptin Sun | Sun Pharmaceutical Industries Europe B.V. | 09.12.2021 | Sitagliptinfumarat | A10BH01 | G |
EU/1/21/1594 | Rybrevant | Janssen-Cilag International N.V. | 09.12.2021 | Amivantamab | L01FX18 | C |
EU/1/21/1593 | Cibinqo | Pfizer Europe MA EEIG | 09.12.2021 | Abrocitinib | D11AH08 | |
EU/1/21/1582 | Artesunate Amivas | Amivas Ireland Limited | 22.11.2021 | Artesunat | P01BE03 | O |
EU/1/21/1592 | Trodelvy | Gilead Sciences Ireland UC | 22.11.2021 | Sacituzumab-Govitecan | L01FX17 | |
EU/1/21/1576 | Brukinsa | BeiGene Ireland Limited | 22.11.2021 | Zanubrutinib | L01EL03 | |
EU/1/21/1569 | Qinlock | Deciphera Pharmaceuticals (Netherlands) B.V. | 18.11.2021 | Ripretinib | L01EX19 | O |
EU/1/21/1555 | Gavreto | Roche Registration GmbH | 18.11.2021 | Pralsetinib | L01EX23 | C |
EU/1/21/1590 | Libmyris | STADA Arzneimittel AG | 18.11.2021 | Adalimumab | L04AB04 | B |
EU/1/21/1583 | Sugammadex Mylan | Mylan IRE Healthcare Limited | 15.11.2021 | Sugammadex | V03AB35 | G |
EU/1/21/1589 | Hukyndra | STADA Arzneimittel AG | 15.11.2021 | Adalimumab | L04AB04 | B |
EU/1/21/1585 | Vumerity | Biogen Netherlands B.V. | 15.11.2021 | Diroximelfumarat | L04AX09 | |
EU/1/21/1588 | Rivaroxaban Mylan | Mylan IRE Healthcare Limited | 12.11.2021 | Rivaroxaban | B01AF01 | G |
EU/1/21/1601 | Ronapreve | Roche Registration GmbH | 12.11.2021 | Casirivimab / Imdevimab | J06BD | |
EU/1/21/1597 | Regkirona | Celltrion Healthcare Hungary Kft. | 12.11.2021 | Regdanvimab | J06BB | |
EU/1/21/1568 | Imatinib Koanaa | Koanaa Healthcare GmbH | 22.09.2021 | Imatinibmesilat | L01EA01 | G |
EU/1/21/1546 | Ozawade | Bioprojet Pharma | 01.09.2021 | Pitolisant | N07XX11 | |
EU/1/21/1577 | Voxzogo | BioMarin International Limited | 26.08.2021 | Vosoritid | M05BX07 | O |
EU/1/21/1570 | Minjuvi | Incyte Biosciences Distribution B.V. | 26.08.2021 | Tafasitamab | L01FX12 | O, C |
EU/1/21/1571 | Abiraterone Mylan | Mylan IRE Healthcare Limited | 20.08.2021 | Abirateronacetat | L02BX03 | G |
EU/1/21/1575 | Bimzelx | UCB Pharma S.A. | 20.08.2021 | Bimekizumab | L04AC21 | |
EU/1/21/1573 | Fingolimod Mylan | Mylan IRE Healthcare Limited | 18.08.2021 | Fingolimod | L04AA27 | G |
EU/1/21/1572 | Byooviz | Samsung Bioepis NL B.V. | 18.08.2021 | Ranibizumab | S01LA04 | B |
EU/1/21/1574 | Evrenzo | Astellas Pharma Europe B.V. | 18.08.2021 | Roxadustat | B03XA05 | |
EU/1/21/1539 | Abecma | Bristol-Myers Squibb Pharma EEIG | 18.08.2021 | Idecabtagen vicleucel | L01 | O, C |
EU/1/21/1567 | Icatibant Accord | Accord Healthcare S.L.U. | 16.07.2021 | Icatibant | B06AC02 | G |
EU/1/21/1565 | Ryeqo | Gedeon Richter Plc. | 16.07.2021 | Relugolix / Estradiol / Norethisteronacetat | H01CC54 | |
EU/1/21/1561 | Verquvo | Bayer AG | 16.07.2021 | Vericiguat | C01DX22 | |
EU/1/21/1566 | Bylvay | Albireo AB | 16.07.2021 | Odevixibat | O, E | |
EU/1/21/1564 | Imcivree | Rhythm Pharmaceuticals Netherlands B.V. | 16.07.2021 | Setmelanotid | A08AA12 | O, O, W |
EU/1/21/1558 | Klisyri | Almirall, S.A. | 16.07.2021 | Tirbanibulin | D06BX03 | |
EU/1/21/1563 | Skysona (zurückgezogen 04.04.2022) | Almirall, S.A. | 16.07.2021 | Elivaldogen autotemcel | N07 | |
EU/1/21/1559 | Enspryng | Roche Registration GmbH | 24.06.2021 | Satralizumab | L04AC19 | O |
EU/1/21/1553 | Abiraterone Krka | Krka d.d., Novo mesto | 24.06.2021 | Abirateronacetat | L02BX03 | G |
EU/1/21/1557 | Jayempi | Nova Laboratories Ireland Limited | 21.06.2021 | Azathioprin | L04AX01 | |
EU/1/21/1560 | Celsunax | Pinax Pharma GmbH | 17.06.2021 | Ioflupan (123I) | V09AB03 | G |
EU/1/21/1556 | Onureg | Bristol-Myers Squibb Pharma EEIG | 17.06.2021 | Azacitidin | L01BC07 | |
EU/1/21/1552 | Koselugo | AstraZeneca AB | 17.06.2021 | Selumetinib | O, C | |
EU/1/21/1554 | Adtralza | LEO Pharma A/S | 17.06.2021 | Tralokinumab | D11AH07 | |
EU/1/21/1551 | Evkeeza | Ultragenyx Germany GmbH | 17.06.2021 | Evinacumab | C10AX | E |
EU/1/21/1549 | Efmody | Diurnal Europe B.V. | 27.05.2021 | Hydrocortison | H02AB09 | |
EU/1/21/1550 | Ponvory | Janssen-Cilag International N.V. | 19.05.2021 | Ponesimod | L04AA50 | |
EU/1/21/1542 | Copiktra | Secura Bio Limited | 19.05.2021 | Duvelisib | L01EM04 | |
EU/1/21/1548 | Lydisilka | Estetra SRL | 19.05.2021 | Drospirenon / Estetrol | G03AA18 | |
EU/1/21/1547 | Drovelis | Gedeon Richter Plc. | 19.05.2021 | Drospirenon / Estetrol | G03AA18 | |
EU/1/20/1517 | Sibnayal | Advicenne S.A. | 30.04.2021 | Kaliumcitrat / Kaliumhydrogencarbonat | A12BA30 | |
EU/1/21/1544 | Orladeyo | Biocryst Ireland Limited | 30.04.2021 | Berotralstat | B06AC06 | |
EU/1/20/1512 | Abiraterone Accord | Accord Healthcare S.L.U. | 26.04.2021 | Abirateronacetat | L02BX03 | G |
EU/1/21/1538 | Jemperli | GlaxoSmithKline (Ireland) Limited | 22.04.2021 | Dostarlimab | L01FF07 | C |
EU/1/20/1516 | Lextemy (zurückgezogen 21.06.2021) | Mylan IRE Healthcare Limited | 21.04.2021 | Bevacizumab | L01XC07 | B |
EU/1/20/1515 | Abevmy | Mylan IRE Healthcare Limited | 21.04.2021 | Bevacizumab | L01XC07 | B |
EU/1/20/1501 | Sogroya | Novo Nordisk A/S | 31.03.2021 | Somapacitan | H01AC07 | O |
EU/1/21/1534 | BroPair Spiromax | Teva B.V. | 26.03.2021 | Salmeterol / Fluticasonpropionat | R03AK06 | |
EU/1/21/1533 | Seffalair Spiromax | Teva B.V. | 26.03.2021 | Salmeterol / Fluticasonpropionat | R03AK06 | |
EU/1/21/1530 | Ontozry | Angelini Pharma S.p.A | 26.03.2021 | Cenobamat | N03AX25 | |
EU/1/21/1537 | Nexpovio | Karyopharm Europe GmbH | 26.03.2021 | Selinexor | L01XX66 | |
EU/1/21/1536 | Thiotepa Riemser | Esteve Pharmaceuticals GmbH | 26.03.2021 | Thiotepa | L01AC01 | G |
EU/1/21/1535 | Pemazyre | Incyte Biosciences Distribution B.V. | 26.03.2021 | Pemigatinib | O, O, C | |
EU/1/21/1532 | Kesimpta | Novartis Ireland Limited | 26.03.2021 | Ofatumumab | L04AA52 | |
EU/1/21/1531 | Evrysdi | Roche Registration GmbH | 26.03.2021 | Risdiplam | M09AX10 | O, A |
EU/1/21/1541 | Dasatinib Accordpharma | Accord Healthcare S.L.U. | 24.03.2021 | Dasatinib | L01EA02 | G |
EU/1/21/1540 | Dasatinib Accord | Accord Healthcare S.L.U. | 24.03.2021 | Dasatinib | L01EA02 | G |
EU/1/20/1509 | Oyavas | STADA Arzneimittel AG | 23.03.2021 | Bevacizumab | L01FG01 | B |
EU/1/21/1525 | Jcovden | Janssen-Cilag International N.V. | 11.03.2021 | COVID-19-Impfstoff (Ad26.COV2-S [rekombinant]) | J07BX03 | C |
EU/1/20/1521 | Lenalidomide Krka d.d. | Krka d.d., Novo mesto | 12.02.2021 | Lenalidomid | L04AX04 | G |
EU/1/20/1527 | Retsevmo | Eli Lilly Nederland B.V. | 11.02.2021 | Selpercatinib | L01EX22 | C |
EU/1/20/1526 | Tuksya | Seagen B.V. | 11.02.2021 | Tucatinib | L01EH03 | |
EU/1/20/1523 | Ogluo | Tetris Pharma B.V | 11.02.2021 | Glucagon | H04AA01 | |
EU/1/20/1520 | Lenalidomide Krka | Krka d.d., Novo mesto | 11.02.2021 | Lenalidomid | L04AX04 | G |
EU/1/20/1519 | Lenalidomide Krka Novo mesto | Krka d.d., Novo mesto | 11.02.2021 | Lenalidomid | L04AX04 | G |
EU/1/20/1513 | Yuflyma | Celltrion Healthcare Hungary Kft. | 11.02.2021 | Adalimumab | L04AB04 | B |
EU/1/20/1511 | Sunitinib Accord | Accord Healthcare S.L.U. | 11.02.2021 | Sunitinib | L01EX01 | G |
EU/1/20/1522 | Lumoxiti (zurückgezogen 23.07.2021) | AstraZeneca AB | 08.02.2021 | Moxetumomab pasudotox | L01X | O |
EU/1/20/1514 | Inrebic | Bristol-Myers Squibb Pharma EEIG | 08.02.2021 | Fedratinib | L01EJ02 | O, O, O |
EU/1/20/1506 | Kirsty | Mylan IRE Healthcare Limited | 05.02.2021 | Insulin aspart | A10AB05 | B |
EU/1/20/1518 | Rukobia | ViiV Healthcare B.V. | 04.02.2021 | Fostemsavir | J05AX29 | |
EU/1/20/1529 | Vaxzevria | AstraZeneca AB | 29.01.2021 | COVID-19-Impfstoff (ChAdOx1-S [rekombinant]) | J07BX03 | C |
EU/1/20/1508 | Enhertu | Daiichi Sankyō Europe GmbH | 18.01.2021 | Trastuzumab deruxtecan | L01XC | C |
EU/1/20/1503 | Heplisav B | Dynavax GmbH | 18.01.2021 | Hepatitis-B-Oberflächenantigen (Hepatitis-B-Impfstoff, rekombinant, adjuvantiert) | J07BC01 | |
EU/1/20/11499 | Onbevzi | Samsung Bioepis NL B.V. | 11.01.2021 | Bevacizumab | L01FG01 | B |
EU/1/20/1504 | Elzonris | Stemline Therapeutics B.V. | 07.01.2021 | Tagraxofusp | L01XX67 | O, E |
EU/1/20/1502 | Roclanda | Santen Oy | 07.01.2021 | Tanoprost / Netarsudil | S01EE51 | |
EU/1/20/1500 | Xofluza | Roche Registration GmbH | 07.01.2021 | Baloxavir marboxil | J05AX25 | |
EU/1/20/1507 | Spikevax | Moderna Biotech Spain, S.L. | 06.01.2021 | Elasomeran, COVID-19 mRNA-Impfstoff (nukleosidmodifiziert)] | J07BX03 | C |
EU/1/20/1528 | Comirnaty | BioNTech Manufacturing GmbH | 21.12.2020 | Tozinameran, COVID-19 mRNA-Impfstoff (nukleosidmodifiziert) | J07BX03 | C |
EU/1/20/1497 | Phesgo | Roche Registration GmbH | 21.12.2020 | Pertuzumab / Trastuzumab | L01XY02 | |
EU/1/20/1498 | Trixeo Aerosphere | AstraZeneca AB | 09.12.2020 | Formoterol / Glycopyrroniumbromid / Budesonid | R03AL11 |
- ↑ siehe Verordnung (EG) Nr. 726/2004
- ↑ diese (im August 2022 angelegte) Liste ist unvollständig und enthält lediglich ab Anfang 2021 erteilte zentrale Zulassungen bzw. Zulassungsempfehlungen
- ↑ Union Register of medicinal products
- ↑ A=accelerated assessment, B=biosimilar, C=conditional approval, E=exceptional circumstances, G=generic, O=orphan designation, W=withdrawn application